Research programme: immunotherapeutics - OnkologixRx

Drug Profile

Research programme: immunotherapeutics - OnkologixRx

Alternative Names: Onko 1

Latest Information Update: 03 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OnkologixRx
  • Developer Larrea Biosciences Corporation; OnkologixRx
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Intracellular signalling peptide and protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gastric cancer
  • Research Influenza virus infections

Most Recent Events

  • 24 Jun 2015 Gordian Holdings plans a phase I trial for Gastric cancer in China and North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top